Under construction – not a live service
Sign in
TerminatedNo phase

Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis

Reason given: Sponsor's decision

Key facts

Where
Cairo, EgyptSee the site

Where in Egypt

  • Air Force Specialized HospitalCairo, EgyptNo longer taking part

Trial details

Who runs it
SYSNAV
Trial code
NCT06346704
Record updated
15 December 2025
Original description
The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis. The Syde® collected data will be compared to on-site conventional clinical endpoints for MS pathology (EDSS, FSS and T25FWT). Subjects with multiple sclerosis will be assessed every 6 months for 2 years.Read full original descriptionShow less

Prospective Longitudinal Monocentric Study to Evaluate the Syde® Digital Endpoint in Patients With Multiple Sclerosis (NHS-MS-EGYPT)

The study aims to assess the validity of real-world activity monitoring by the Syde® wearable device in subjects with multiple slclerosis. The Syde® collected data will be compared to on-site conventional clinical endpoints for MS pathology (EDSS, FSS and T25FWT). Subjects with multiple sclerosis will be assessed every 6 months for 2 years.

Inclusion: Male or female subject aged from 18 to 65 years old; Signed informed consent and ability to comply with study and follow-up; Diagnosed with MS base on 2017 McDonald criterion; EDSS ≤ 5.5; No clinical or radiological relapse within the last 3 months; For patient under treatment, the molecule and its dose should be stable about 2 months before inclusion; Subject willing and able to comply to all study procedures including the Syde® related ones.

Exclusion: Previous or current disorder with an impact on current ambulation or motor function; Patient who have had surgery or traumatic injury in upper or lower limb within the last 6 months before the inclusion or patients who have had major surgery or trauma within the last 6 months before the inclusion; Patient with a cognitive or communicational disorder disturbing the understanding of the tasks or data collection.

ClinicalTrials.gov NCT06346704